Lercanidipin Actavis

Lercanidipine, the active ingredient in Lercanidipin Actavis, is a calcium channel blocker presented as an oral tablet for systemic use. It lowers elevated blood pressure and is indicated for the management of hypertension in adult patients, and is commonly prescribed as part of a comprehensive blood pressure management plan.

GNH USA supplies Lercanidipin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution for this antihypertensive medication.

Lercanidipine is used to treat conditions related to elevated vascular resistance and high blood pressure. Hypertension: lowers systolic and diastolic blood pressure in adults with primary hypertension. Essential hypertension: helps achieve guideline‑recommended blood pressure targets, either as monotherapy or in combination. Isolated systolic hypertension: provides effective blood pressure reduction in elderly patients with isolated systolic hypertension.

Lercanidipine may be associated with several adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects: - Headache: mild to moderate headache occurring shortly after dose initiation. - Flushing: transient facial or upper body flushing. - Peripheral edema: swelling of ankles or lower limbs. - Dizziness: light‑headed sensation, especially when standing quickly.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Angioedema: swelling of face, lips, tongue or throat. - Myocardial infarction: rare occurrence of heart attack.

When prescribing Lercanidipine, clinicians should consider several precautionary measures to ensure safe use. - Assess cardiovascular status: evaluate for existing low blood pressure or heart failure before initiating therapy. - Monitor blood pressure: check regularly after starting treatment and after dose adjustments. - Caution in hepatic impairment: dose may need adjustment in patients with liver dysfunction. - Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. - Drug interactions: review concomitant medications that affect cytochrome P450 3A4. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Lercanidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: concurrent use with ketoconazole, itraconazole or clarithromycin can markedly increase plasma levels. - Grapefruit juice: may raise drug concentration and risk of hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: rifampicin or carbamazepine may reduce effectiveness. - Other antihypertensives: additive blood pressure lowering when combined with beta‑blockers or ACE inhibitors. - Diuretics: may enhance orthostatic hypotension.